CRG and Clayco to Develop, Design and Build Pfizer R&D and Process Development Facility
$250 million investment expected to bring quality jobs to the St. Louis region, increase R&D capabilities.
CRG is providing turnkey build-to-suit services to complete the new BioPlace for Pfizer in Chesterfield, Missouri. CRG is collaborating with Clayco, the design-builder on the project, for this world-class office and laboratory space. As one of the world’s premier innovative biopharmaceutical companies, Pfizer has entrusted CRG and Clayco to deliver a facility that reflects its highest standards for excellence, quality, safety and value.
The dual-purpose structure will be comprised of 285,000 square feet of laboratory and office space. The design partnership of Forum Studio and Ewing Cole merged the expertise and talents of both firms where the unique combination of both research and development labs combined with office and meeting spaces creates one of the most progressive facilities in the pharma industry. The architecture, landscape design, engineering, interior and lab/process was also designed by Forum and EwingCole.
The new campus will be owned by Pfizer and will bring together more than 450 employees who currently work at multiple locations that the company leases in the St. Louis area. Pfizer expects to hire an additional 80 employees over the coming years to support research at the site. Construction is expected to be complete by mid-2019.
“Our team came together quickly; the great chemistry was easy to see and the results we’re achieving are proof that true integration within a develop-design-build project can outshine more traditional methods of delivery,” said Kirk Warden, Clayco executive vice president and partner. “The collaboration between developers, designers, builders, engineers and the many owner groups is leading to a state-of-the-art facility that will offer the St. Louis Pfizer family a spacious and collaborative environment with great views into the surrounding wooded property and plenty of daylight reaching every interior space.”
Representatives from Clayco, alongside Pfizer officials and local dignitaries, broke ground on the project June 27, 2017. When complete, the facility will provide approximately 285,000 square feet of R&D space to house Pfizer’s BioTherapeutics Pharmaceutical Sciences group and enabling partners. New state-of-the-art features of the campus will include a floor plan that provides flexible laboratory layouts, scientific casework and utility hookups, open office and collaboration spaces and increased conferencing technologies where researchers can collaborate.